
    
      The total study duration per patient is 70-105 days (for patients without drug washout/switch
      period), and up to 175 days (for patients with drug washout/switch period), including 2-30
      days of screening, 5 days of run-in period, 56 days of treatment period, and a 7-14 days of
      follow-up period.
    
  